Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group. Inoue A, et al. Among authors: morita s. J Clin Oncol. 2009 Mar 20;27(9):1394-400. doi: 10.1200/JCO.2008.18.7658. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224850 Clinical Trial.
Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis.
Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, Sonobe M, Morita S, Date H, Hiraoka M. Matsuo Y, et al. Among authors: morita s. Eur J Cancer. 2014 Nov;50(17):2932-8. doi: 10.1016/j.ejca.2014.09.006. Epub 2014 Sep 30. Eur J Cancer. 2014. PMID: 25281527
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S. Hattori Y, et al. Among authors: morita s. Lung Cancer. 2015 Feb;87(2):136-40. doi: 10.1016/j.lungcan.2014.12.007. Epub 2014 Dec 19. Lung Cancer. 2015. PMID: 25553650 Clinical Trial.
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Nishino K, Imamura F, Kumagai T, Katakami N, Hata A, Okuda C, Urata Y, Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M, Morita S, Negoro S. Nishino K, et al. Among authors: morita s. Lung Cancer. 2015 Aug;89(2):146-53. doi: 10.1016/j.lungcan.2015.05.022. Epub 2015 Jun 6. Lung Cancer. 2015. PMID: 26093793 Clinical Trial.
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S. Nishiyama A, et al. Among authors: morita s. Lung Cancer. 2015 Sep;89(3):301-5. doi: 10.1016/j.lungcan.2015.06.017. Epub 2015 Jun 25. Lung Cancer. 2015. PMID: 26141215
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Yamada K, Aono H, Hosomi Y, Okamoto H, Kato T, Komase Y, Nishikawa M, Azuma K, Takeoka H, Okuma Y, Nakahara Y, Sato A, Oba MS, Morita S, Kunitoh H, Watanabe K. Yamada K, et al. Among authors: morita s. Eur J Cancer. 2015 Sep;51(14):1904-10. doi: 10.1016/j.ejca.2015.06.120. Epub 2015 Jul 11. Eur J Cancer. 2015. PMID: 26174465 Clinical Trial.
3,475 results